BeOne Medicines (NASDAQ:ONC) Shares Gap Down - Time to Sell?

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report)'s stock price gapped down prior to trading on Friday . The stock had previously closed at $254.49, but opened at $245.51. BeOne Medicines shares last traded at $242.81, with a volume of 52,203 shares trading hands.

Wall Street Analysts Forecast Growth

ONC has been the topic of several research analyst reports. TD Securities reissued a "buy" rating and set a $334.00 target price on shares of BeOne Medicines in a research note on Thursday, April 24th. Guggenheim raised their target price on BeOne Medicines from $348.00 to $350.00 and gave the company a "buy" rating in a report on Thursday, May 8th. Sanford C. Bernstein set a $259.00 price target on shares of BeOne Medicines in a report on Thursday, March 13th. JPMorgan Chase & Co. lifted their price objective on shares of BeOne Medicines from $317.00 to $321.00 and gave the stock an "overweight" rating in a research report on Friday. Finally, JMP Securities set a $348.00 target price on shares of BeOne Medicines in a research report on Friday, February 28th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and an average price target of $320.67.

BeOne Medicines Price Performance

The company has a current ratio of 1.96, a quick ratio of 1.71 and a debt-to-equity ratio of 0.05. The stock has a 50-day moving average price of $247.69. The company has a market cap of $26.78 billion, a price-to-earnings ratio of -65.67 and a beta of 0.30.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, beating analysts' consensus estimates of ($0.71) by $1.93. The firm had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.12 billion. BeOne Medicines had a negative return on equity of 7.55% and a negative net margin of 9.40%. On average, equities analysts forecast that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Xiaodong Wang sold 41,760 shares of the company's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $223.50, for a total value of $9,333,360.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO John Oyler sold 3,174 shares of BeOne Medicines stock in a transaction on Monday, June 23rd. The shares were sold at an average price of $261.61, for a total transaction of $830,350.14. The disclosure for this sale can be found here. Insiders have sold a total of 203,452 shares of company stock valued at $51,856,379 over the last ninety days. Company insiders own 6.62% of the company's stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.